Pre-Market Research Reports on Generic Drugs Stocks — Tricida, Zoetis, Adamas Pharma, and Allergan

NEW YORK, July 23, 2018 /PRNewswire/ —

If you want a free Stock Review on TCDA, ZTS, ADMS, and AGN sign up now at On Friday, key US indices were bearish as the NASDAQ Composite finished the trading session down 0.07%; the Dow Jones Industrial Average edged 0.03% lower; and the S&P 500 was down 0.09%. Before the US markets open this morning, appraises these four Drugs – Generic equities: Tricida Inc. (NASDAQ: TCDA), Zoetis Inc. (NYSE: ZTS), Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), and Allergan PLC (NYSE: AGN). All you have to do is sign up today for this free limited time offer by clicking the link below.


USA-headquartered Tricida Inc.’s stock finished Friday’s session 1.30% lower at $29.50. A total volume of 75,954 shares was traded. The stock has advanced 13.46% on an YTD basis. Shares of the Company, which focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease, are trading below its 50-day and 200-day moving averages by 2.64% and 2.64%, respectively.

On July 02nd, 2018, Tricida announced the closing of its initial public offering of 13,455,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,755,000 shares of common stock for total gross proceeds of approximately $255.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The shares began trading on The NASDAQ Global Select Market on June 28th, 2018 under the symbol “TCDA”. Get the full research report on TCDA for free by clicking below at:


Shares in USA-based Zoetis Inc. ended at $85.29, down 0.15% from the last trading session. The stock recorded a trading volume of 1.98 million shares. The Company’s shares have gained 35.92% in the last twelve months and 18.39% on an YTD basis. Shares of the Company, which discovers, develops, manufactures, and markets veterinary vaccines and medicines in the US and internationally, are trading above its 200-day moving average by 9.43%. Moreover, shares of Zoetis have an RSI of 48.25 and have a dividend yield of 0.59%.

On June 29th, 2018, Zoetis announced that it will host a webcast and conference call on August 02nd, 2018, at 8:30 a.m. ET. CEO, Juan Ramón Alaix, and Executive Vice President and CFO, Glenn David, will review the Company’s Q2 2018 financial results and respond to questions from financial analysts during the call. To experience our free membership services anytime/ anywhere and access the free report on ZTS, click to register at:

Adamas Pharmaceuticals 

USA-based Adamas Pharmaceuticals Inc.’s stock ended last Friday’s session 0.15% lower at $27.09 with a total trading volume of 356,488 shares. The Company’s shares have advanced 53.75% in the last twelve months. The stock is trading below its 50-day moving average by 2.24%. Additionally, shares of Adamas Pharma, which discovers, develops, and sells therapies for chronic neurologic disorders, have an RSI of 54.04.

On July 09th, 2018, Adamas Pharma announced that the compensation committee of its Board of Directors granted two new employees the option to purchase an aggregate of 29,531 shares of its common stock, at a per share exercise price of $25.74, the closing trading price that day, and restricted stock units to acquire 4,921 shares of the common stock.

On July 16th, 2018, research firm H.C. Wainwright initiated a ‘Buy’ rating on the Company’s stock, with a target price of $45 per share. Join our big investor community at Stock Trader Report now and get your free report on ADMS at:


On Friday, shares in USA-headquartered Allergan PLC recorded a trading volume of 1.50 million shares. The stock finished the day 0.92% lower at $171.79. The Company’s shares have advanced 8.38% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.26% and 1.46%, respectively. Furthermore, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have an RSI of 51.67 and have a dividend yield of 1.68%.

On July 10th, 2018, Allergan announced the launch of a new, over-the-counter artificial tear formulation, REFRESH® REPAIR Lubricant Eye Drops. REFRESH® REPAIR is the latest addition to the REFRESH® portfolio and is the first and only artificial tear in the US formulated with carboxymethylcellulose, hyaluronic acid, and osmoprotectants. Know more about AGN in our free research coverage at:

Stock Trader Report: 

Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

STR has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If youre a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 917-979-2038

Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Stock Trader Report

Source link Google News

Leave a Reply

Your email address will not be published. Required fields are marked *